A New Look, New Direction for Society of Nuclear Medicine

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 8
Volume 11
Issue 8

LOS ANGELES-The Society of Nuclear Medicine (SNM) has changed its logo for the first time in its 49-year history. The new logo is designed to create a bright, fresh look for SNM, Alan Maurer, MD, said at the Society’s 49th Annual Meeting. Dr. Maurer, director of nuclear medicine, Temple University, is the immediate past president of the SNM.

LOS ANGELES—The Society of Nuclear Medicine (SNM) has changed its logo forthe first time in its 49-year history. The new logo is designed to create abright, fresh look for SNM, Alan Maurer, MD, said at the Society’s 49th AnnualMeeting. Dr. Maurer, director of nuclear medicine, Temple University, is theimmediate past president of the SNM.

The new logo retains the roots and heritage of SNM by keeping the atomic orbital symbol. A tagline in the new logo, "advancing molecular imaging," is seen emerging from the atomic orbital. It replaces the caduceus holding the atomic orbital in the old logo.

Although molecular imaging has always been an important part of nuclear medicine, the new tagline identifies the organization as being on the cutting edge of molecular imaging technology, said Michael Gelfand, MD, the new SNM president. "The new logo represents a first step in creating a new and evolving identity for SNM," he said. 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content